SOURCE: Xtalks

Xtalks Webinars

March 16, 2017 08:12 ET

Natural History vs. Registry Studies in Rare Disease, a New Webinar Presented by Premier Research, Hosted by Xtalks

TORONTO, ON--(Marketwired - March 16, 2017) - The live broadcast taking place on Tuesday, April 4, 2017 at 11:00am EDT (4pm BST/UK) will discuss key elements such as:

  • The importance of natural history information in rare disease research and the regulatory importance of comprehensive disease data
  • The difference between registry and natural history studies, and how to decide which will better meet your needs
  • How to design and conduct a registry or natural history study, and what resources are available to help you proceed

Sound drug development requires a comprehensive understanding of the disease being treated. To design reliable clinical studies and achieve meaningful outcome measures, researchers must apply known etiology and thorough knowledge of the disease's progression. For rare diseases, this information is often minimal at best: patient numbers are small and historical data is spread across treating physicians who operate around the world.

It's essential that pharma companies, patient advocates, and other stakeholders use data on the natural history of these diseases to drive discussion and formulate drug development strategy. There are two prevalent data collection approaches: registry studies, which may include broad collection of defined data, and natural history studies, used for controlled, detailed collection of data that is subject to regulatory scrutiny.

Join Angi Robinson, Executive Director of Pediatrics & Rare Disease and Juliet Moritz, Executive Director of Rare Disease & General Medicine both from Premier Research for an educational webinar. For details or to register for this complimentary event visit: http://xtalks.com/Natural-History-Registry-Studies-in-Rare-Disease.ashx

About Premier Research

Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical, and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs, with a special focus on addressing unmet needs in areas such as analgesia, CNS, rare diseases, medical device and diagnostics, oncology, and pediatric research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.

To learn more about Premier Research visit: premier-research.com

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2017/3/16/11G133292/Images/Premier_Research_logo-398906951265.jpg

Contact Information